Chronic inducible urticaria: confirmation through challenge tests and response to treatment
Carregando...
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2020
Título da Revista
ISSN da Revista
Título do Volume
Editora
INST ISRAELITA ENSINO & PESQUISA ALBERT EINSTEIN
Citação
EINSTEIN-SAO PAULO, v.18, article ID eAO5175, 8p, 2020
Resumo
Objective: To evaluate the positivity of challenge tests of patients suspected of chronic inducible urticaria and the response to treatment. Methods: A retrospective study of electronic medical records of patients suspected of chronic inducible urticaria. All patients were submitted to challenge tests with triggering stimuli, according to the clinical history and, subsequently, the response to drug treatment was evaluated. Results: A total of 191 patients with suspected chronic inducible urticaria were included. It was confirmed in 118 patients and 122 positive tests (4 patients with 2 different positive tests). Most had dermographic urticaria (70.3%), followed by cholinergic urticaria (17.8%). Regarding treatment, 28% responded to antihistamine in licensed doses, 34.7% with increased doses, 9.3% responded to the addition of another medication. The concomitance of chronic inducible urticaria and chronic spontaneous urticaria was found in 35.3% of patients, being more frequent in females, with longer time to control symptoms and higher frequency of cholinergic urticaria. Conclusion: The confirmation of chronic inducible urticaria in patients with this suspicion, after challenge tests, was high. There was a good response to antihistamine. In the concomitance of chronic spontaneous urticaria, longer time to control symptoms and higher frequency of cholinergic urticaria were observed.
Palavras-chave
Urticaria, Angioedema, Diagnosis, Drug therapy, Dose-response relationship, drug
Referências
- Abajian M, 2014, IMMUNOL ALLERGY CLIN, V34, P73, DOI 10.1016/j.iac.2013.09.010
- Balp MM, 2017, DERMATOLOGY THER, V7, P547, DOI 10.1007/s13555-017-0200-7
- BLACK AK, 1979, LANCET, V2, P964
- Black AK, 1996, CLIN EXP DERMATOL, V21, P424, DOI 10.1111/j.1365-2230.1996.tb00146.x
- Dias GAC, 2016, AN BRAS DERMATOL, V91, P754, DOI 10.1590/abd1806-4841.20165071
- Curto-Barredo L, 2018, ACTA DERM-VENEREOL, V98, P641, DOI 10.2340/00015555-2941
- Dressler C, 2018, J ALLERGY CLIN IMMUN, V141, P1726, DOI 10.1016/j.jaci.2018.01.031
- Duarte RA, 2018, ARQ ASMA ALERG IMUNO, V2, P434
- Geller M, 2007, EINSTEIN-SAO PAULO, V5, P273
- Grob JJ, 2005, BRIT J DERMATOL, V152, P289, DOI 10.1111/j.1365-2133.2005.06385.x
- Guillen-Aguinaga S, 2016, BRIT J DERMATOL, V175, P1153, DOI 10.1111/bjd.14768
- Kocaturk E, 2017, J DERMATOL SCI, V87, P60, DOI 10.1016/j.jdermsci.2017.02.283
- KontouFili K, 1997, ALLERGY, V52, P504, DOI 10.1111/j.1398-9995.1997.tb02593.x
- LEIGH IM, 1974, T ST JOHNS HOSP DERM, V60, P40
- LEIGH IM, 1975, BRIT J DERMATOL, V92, P191, DOI 10.1111/j.1365-2133.1975.tb03057.x
- Lima SO, 2008, REV BRAS ALERG IMUNO, V31, P220
- Magerl M, 2016, ALLERGY, V71, P780, DOI 10.1111/all.12884
- Maurer M, 2018, J ALLER CL IMM-PRACT, V6, P1119, DOI 10.1016/j.jaip.2018.03.007
- Maurer M, 2018, J ALLERGY CLIN IMMUN, V141, P638, DOI 10.1016/j.jaci.2017.06.032
- Metz M, 2011, INT ARCH ALLERGY IMM, V154, P177, DOI 10.1159/000320233
- ODonnell BF, 1997, BRIT J DERMATOL, V136, P197
- RAMSAY CA, 1977, ARCH DERMATOL, V113, P1222, DOI 10.1001/archderm.113.9.1222
- Sanchez J, 2017, J ALLER CL IMM-PRACT, V5, P464, DOI 10.1016/j.jaip.2016.09.029
- Schoepke N, 2015, J EUR ACAD DERMATOL, V29, P708, DOI 10.1111/jdv.12661
- Silpa-archa N, 2011, J EUR ACAD DERMATOL, V25, P1194, DOI 10.1111/j.1468-3083.2010.03951.x
- Trevisonno J, 2015, POSTGRAD MED, V127, P565, DOI 10.1080/00325481.2015.1045817
- WARIN RP, 1987, BRIT J DERMATOL, V116, P742, DOI 10.1111/j.1365-2133.1987.tb05913.x
- Zuberbier H C Torsten, 2014, IMMUNOL ALLERGY CLIN, V34, pxix
- Zuberbier T, 2018, ALLERGY, V73, P1393, DOI 10.1111/all.13397